Navigation Links
The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
Date:5/2/2013

sGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com  


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
2. Allscripts adopts majority voting policy for directors
3. BD Completes Sale of Majority of Discovery Labware Unit
4. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
5. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
6. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
7. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
10. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
11. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 The National Association of Managed ... released the NAMCP Medical Technologies Dossier Template © ... © , which provide medical directors and manufacturers ... devices or diagnostics that accounts for evidence-based development ... technology types (instead of having to attempt to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
Breaking Medicine Technology:NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... Mass., Oct. 26 DUSA Pharmaceuticals, Inc.® (Nasdaq: ... dermatology announced today that it has been named to ... consecutive year, Deloitte recognized DUSA as one of the ... and clean technology companies in North America.  Rankings are ...
... Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop... -- INGELHEIM, Germany and ROCKVILLE, Md., Oct. 26 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Medicine Technology:DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 2Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 3Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 4Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 5Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 6Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 7Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 8Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 9Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics 10
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Almost all the ... in veins are equally safe and effective, new ... effectiveness of treatments for such blood clots as ... in a lung), Canadian researchers analyzed outcomes associated ... heparin (LMWH) and fondaparinux in combination with vitamin ...
(Date:9/16/2014)... Dennis Thompson HealthDay ... -- A combination drug therapy aimed at opening the ... treatment for older adults with chronic obstructive pulmonary disease ... COPD patients who received a combination of ... to die or require hospitalization because of their breathing ...
(Date:9/16/2014)... York (PRWEB) September 16, 2014 ... filed against C.R. Bard, Inc. continue to move ... U.S. District Court, Southern District of West Virginia, ... dated September 15, 2014, the Court has determined ... to the proceeding. The Order indicates that the ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Novatus, a ... a new office in London, UK, and appointed Jim ... in Europe, the expansion will allow Novatus to target ... its European customers. , “Novatus is ... and London is an ideal location to establish our ...
(Date:9/16/2014)... The child molestation victim lawyers at Estey ... who, according to case documents, were allegedly sexually abused ... San Diego. The victims were allegedly in elementary school ... of the defendant in the case remains confidential, per ... noted that no criminal charges were filed against the ...
Breaking Medicine News(10 mins):Health News: Most Treatments for Blood Clots Appear Safe, Effective 2Health News:Combo Therapy Best for COPD: Study 2Health News:Combo Therapy Best for COPD: Study 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Novatus Expands European Operations with a New Office in London 2Health News:ESTEY BOMBERGER Announces $3 Million Settlement for Sexual Abuse at San Diego Private School 2
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. (CTI) ... Drug Administration (FDA) has accepted and has filed for review the ... or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User Fee ... review of the pixantrone NDA by September 4th 2009. ...
... at the time of diagnosis do not live as long ... conclusion of a new study to be published in the ... journal of the American Cancer Society. The authors of the ... marital separation may compromise an individual,s immune system and lead ...
... factor for active tuberculosis (TB) disease, according to a new ... analyzed data from nearly 17,000 individuals in Taiwan as part ... past studies have reported increased mortality among TB patients who ... effect of smoking on active TB incidence using a longitudinal ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Over one-hundred business ... , ... -- Rooted in Newtonian and quantum science, ancient spiritual and healing traditions, and clinical studies, ... book ColorAlchemy , by Jami Lin teaches people how to harness a daily color ...
... diagnosis of Idiopathic Pulmonary Fibrosis is not much better ... the survival rate is less than three years. ... that targeting of a novel gene utilizing genetic and ... mice and will be developed for future testing in ...
Cached Medicine News:Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:Smoking increases risk of developing active TB 2Health News:Smoking increases risk of developing active TB 3Health News:New technique can help diagnose mesothelioma 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 2Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 3Health News:Business Association in Denver Invites Award-winning Author of ColorAlchemy to Provide Motivation to Energize Performance and Stimulate Success Using the Color Red 4Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2
... System is a point-of-care system designed for ... referred to as Platelet Rich Plasma - ... a small sample of blood. The Symphony ... factors, which are found in the platelets. ...
... Dual Imaging Color Module Leica combines precision microscopy ... important and necessary patient data can be displayed ... optical platform on the Leica OH3, OHS1, MS3 ... highest brightness, contrast >300:1, true color and resolution ...
... Headlight mounted micro video camera has ... pictures in areas otherwise invisible to all ... capabilities. The system may be used for ... eliminating crowding of the sterile area and ...
... DXC-S500 consists of 2-piece body, one is CHU ... and built-in Peltier cooling devices, the other is ... monitor. CCU incorporates IEEE1394 interface for direct connection ... card slot for storing images into memory stick ...
Medicine Products: